Gilead Sciences, Inc. (GILD)
Largest Insider Buys in Sector
GILD Stock Price History Chart
GILD Stock Performance
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Insider Activity of Gilead Sciences, Inc.
Over the last 12 months, insiders at Gilead Sciences, Inc. have bought $0 and sold $49.31M worth of Gilead Sciences, Inc. stock.
On average, over the past 5 years, insiders at Gilead Sciences, Inc. have bought $0 and sold $13.58M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $2M was made by WOLD OLSEN PER (director) on 2015‑02‑06.
List of Insider Buy and Sell Transactions, Gilead Sciences, Inc.
| 2024-11-29 | Sale | Chief Financial Officer | 248,645 0.02% | $92.76 | $23.07M | -0.22% | ||
| 2024-11-27 | Sale | Chief Medical Officer | 164,211 0.0131% | $91.92 | $15.09M | -0.03% | ||
| 2024-11-26 | Sale | director | 6,788 0.0005% | $91.39 | $620,356 | +1.13% | ||
| 2024-11-06 | Sale | Chief Medical Officer | 25,590 0.0021% | $91.50 | $2.34M | +0.75% | ||
| 2024-11-06 | Sale | Chief Commercial Officer | 5,000 0.0004% | $91.28 | $456,400 | +0.75% | ||
| 2024-10-01 | Sale | Chief Medical Officer | 2,000 0.0002% | $83.83 | $167,660 | +6.98% | ||
| 2024-09-12 | Sale | Chief Medical Officer | 21,246 0.0017% | $84.50 | $1.8M | +7.23% | ||
| 2024-09-12 | Sale | Chief Commercial Officer | 29,357 0.0024% | $83.78 | $2.46M | +7.23% | ||
| 2024-08-28 | Sale | Chief Commercial Officer | 9,513 0.0008% | $78.03 | $742,299 | +10.39% | ||
| 2024-08-13 | Sale | Chief Commercial Officer | 5,490 0.0004% | $73.98 | $406,150 | 0.00% | ||
| 2024-07-01 | Sale | Chief Medical Officer | 2,000 0.0002% | $68.63 | $137,260 | 0.00% | ||
| 2024-04-01 | Sale | Chief Medical Officer | 2,000 0.0002% | $72.96 | $145,920 | +3.09% | ||
| 2024-02-29 | Sale | Chief Medical Officer | 8,230 0.0007% | $72.74 | $598,624 | +2.65% | ||
| 2024-02-28 | Sale | Chief Medical Officer | 2,000 0.0002% | $73.18 | $146,360 | +1.76% | ||
| 2024-01-16 | Sale | Chief Financial Officer | 5,000 0.0004% | $85.78 | $428,900 | -13.57% | ||
| 2024-01-09 | Sale | Chief Commercial Officer | 8,242 0.0007% | $85.23 | $702,466 | -13.52% | ||
| 2023-10-17 | Sale | Chief Financial Officer | 5,000 0.0004% | $80.00 | $400,017 | -6.68% | ||
| 2023-09-12 | Sale | Chief Medical Officer | 1,501 0.0001% | $76.99 | $115,562 | -2.57% | ||
| 2023-07-20 | Sale | Chief Financial Officer | 5,000 0.0004% | $80.00 | $400,000 | -5.94% | ||
| 2023-06-13 | Sale | Chief Medical Officer | 1,485 0.0001% | $76.90 | $114,197 | -2.34% |
Insider Historical Profitability
| Dickinson Andrew D | Chief Financial Officer | 138919 0.0111% | $92.07 | 0 | 4 | |
| Parsey Merdad | Chief Medical Officer | 80801 0.0065% | $92.07 | 0 | 14 | |
| Mercier Johanna | Chief Commercial Officer | 73127 0.0059% | $92.07 | 0 | 6 | |
| Bluestone Jeffrey | director | 8920 0.0007% | $92.07 | 0 | 1 | |
| MARTIN JOHN C | director | 2877762 0.2309% | $92.07 | 1 | 157 | +15.06% |
| MILLIGAN JOHN F | President and CEO | 1165924 0.0936% | $92.07 | 1 | 53 | +12.4% |
| DAVIGNON ETIENNE | director | 1160186 0.0931% | $92.07 | 0 | 10 | |
| MOORE GORDON EARLE | director | 698640 0.0561% | $92.07 | 0 | 2 | |
| DENNY JAMES M | director | 281158 0.0226% | $92.07 | 0 | 22 | |
| YOUNG KEVIN | Chief Operating Officer | 216418 0.0174% | $92.07 | 0 | 22 | |
| PERRY MARK L | EVP Operations | 196340 0.0158% | $92.07 | 0 | 4 | |
| YANG TAIYIN | SVP, Pharm Dev & Mfg | 146381 0.0117% | $92.07 | 0 | 6 | |
| BISCHOFBERGER NORBERT W | EVP, R&D and CSO | 127936 0.0103% | $92.07 | 0 | 52 | |
| WILSON GAYLE E | director | 124499 0.01% | $92.07 | 0 | 10 | |
| Washington Robin L | EVP, CFO | 105405 0.0085% | $92.07 | 0 | 45 | |
| WOLD OLSEN PER | director | 97854 0.0079% | $92.07 | 4 | 3 | +18.87% |
| SHULTZ GEORGE P | director | 80000 0.0064% | $92.07 | 0 | 1 | |
| Carter Paul Rutherford | EVP Commercial Ops | 62305 0.005% | $92.07 | 0 | 39 | |
| LEE WILLIAM A | SVP, Research | 58399 0.0047% | $92.07 | 0 | 21 | |
| Cogan John Francis | director | 54860 0.0044% | $92.07 | 0 | 44 | |
| Alton Gregg H | EVP,Corporate &Medical Affairs | 44426 0.0036% | $92.07 | 0 | 165 | |
| BERG PAUL | director | 32000 0.0026% | $92.07 | 0 | 57 | |
| Pletcher Brett A | EVP,Corp Affairs & Gen Counsel | 32576 0.0026% | $92.07 | 0 | 23 | |
| Whitley Richard James | director | 31122 0.0025% | $92.07 | 0 | 19 | |
| Wilfong Diane E. | SVP, Controller & CAO | 28333 0.0023% | $92.07 | 0 | 4 | |
| Metza Kristen | SVP, Human Resources | 25305 0.002% | $92.07 | 0 | 22 | |
| MADIGAN JOHN W | director | 16761 0.0013% | $92.07 | 0 | 2 | |
| HILLS CARLA A | director | 2742 0.0002% | $92.07 | 2 | 0 | <0.0001% |
| Meyers James R | EVP Worldwide Commercial Ops | 2715 0.0002% | $92.07 | 0 | 4 | |
| MOORE NICHOLAS G | director | 0 0% | $92.07 | 0 | 10 | |
| TOOLE JOHN J | SVP, Clinical Research | 0 0% | $92.07 | 0 | 11 | |
| CARACCIOLO ANTHONY | SVP, Manufacturing | 0 0% | $92.07 | 0 | 4 | |
| Rodriguez Javier | director | 0 0% | $92.07 | 0 | 1 | |
| Lofton Kevin E | director | 0 0% | $92.07 | 0 | 1 |
Institutional Investor Ownership
| BlackRock | $8.98B | 9.84 | 122.53M | -0.21% | -$19.19M | 0.2 | |
| The Vanguard Group | $8.4B | 9.21 | 114.73M | +2.6% | +$213.17M | 0.16 | |
| Capital World Investors | $6.19B | 6.78 | 84.5M | +1.36% | +$83.01M | 1.03 | |
| Capital Research Global Investors | $4.49B | 4.92 | 61.25M | +2.66% | +$116.41M | 1.02 | |
| State Street | $4.23B | 4.63 | 57.7M | -3.08% | -$134.16M | 0.17 | |
| Dodge & Cox | $2.43B | 2.66 | 33.17M | -0.38% | -$9.34M | 1.41 | |
| Geode Capital Management | $1.93B | 2.12 | 26.35M | +4.25% | +$78.58M | 0.16 | |
| Wellington Management Company | $1.51B | 1.65 | 20.57M | +10.4% | +$141.93M | 0.26 | |
| Morgan Stanley | $1.32B | 1.45 | 18.01M | +1.19% | +$15.52M | 0.1 | |
| Fidelity Investments | $1.29B | 1.41 | 17.59M | +2.87% | +$35.96M | 0.09 | |
| BNY Mellon | $1.07B | 1.18 | 14.67M | -5.33% | -$60.46M | 0.2 | |
| Northern Trust | $969.04M | 1.06 | 13.23M | -5.68% | -$58.35M | 0.16 | |
| Legal & General | $902.53M | 0.99 | 12.32M | -1.13% | -$10.32M | 0.21 | |
| Invesco | $826.26M | 0.91 | 11.28M | -3.17% | -$27.02M | 0.17 | |
| Dimensional Fund Advisors | $743.06M | 0.81 | 10.14M | +3.69% | +$26.44M | 0.19 | |
| Ubs Asset Management Americas Inc | $697.69M | 0.77 | 9.52M | +0.83% | +$5.77M | 0.25 | |
| Amundi | $640.29M | 0.76 | 9.5M | -9.7% | -$68.74M | 0.27 | |
| Nuveen | $627.74M | 0.69 | 8.57M | -25.7% | -$217.16M | 0.18 | |
| CalPERS | $553.72M | 0.61 | 7.56M | -3.63% | -$20.88M | 0.39 | |
| Deutsche Bank | $549.4M | 0.6 | 7.5M | -2.48% | -$13.99M | 0.25 | |
| Charles Schwab | $539.65M | 0.59 | 7.37M | +1.18% | +$6.28M | 0.12 | |
| Royal Bank of Canada | $529.3M | 0.58 | 7.23M | -32.07% | -$249.9M | 0.13 | |
| The Manufacturers Life Insurance Company | $522.46M | 0.57 | 7.13M | -6.54% | -$36.59M | 0.48 | |
| Wells Fargo | $517.67M | 0.57 | 7.07M | -0.78% | -$4.05M | 0.14 | |
| AllianceBernstein | $511.19M | 0.56 | 6.98M | -3.96% | -$21.08M | 0.18 | |
| Barclays | $498.64M | 0.55 | 6.81M | +19.85% | +$82.58M | 0.23 | |
| JPMorgan Chase | $484.5M | 0.53 | 6.61M | +34.44% | +$124.12M | 0.04 | |
| Bank of America | $484.66M | 0.53 | 6.62M | +2.38% | +$11.28M | 0.05 | |
| Pacer Advisors Inc | $463.3M | 0.51 | 6.32M | +25.33% | +$93.63M | 1.17 | |
| LSV Asset Management | $415.82M | 0.46 | 5.68M | -4.24% | -$18.4M | 0.86 | |
| VanEck | $408.16M | 0.45 | 5.57M | +11.61% | +$42.47M | 0.62 | |
| Citadel Advisors LLC | $389.81M | 0.43 | 5.32M | +1,226.43% | +$360.43M | 0.22 | |
| Federated Hermes | $387.07M | 0.42 | 5.28M | +39.52% | +$109.65M | 0.9 | |
| Goldman Sachs | $380.21M | 0.42 | 5.19M | -46.16% | -$326.04M | 0.07 | |
| Two Sigma Advisers LP | $372.08M | 0.41 | 5.08M | +334.41% | +$286.43M | 0.61 | |
| Arrowstreet Capital, Limited Partnership | $369.65M | 0.41 | 5.05M | -39.77% | -$244.06M | 0.35 | |
| ClearBridge Investments | $354.35M | 0.39 | 4.84M | -1.71% | -$6.16M | 0.28 | |
| HSBC | $327.44M | 0.36 | 4.47M | +37.85% | +$89.91M | 0.23 | |
| Renaissance Technologies | $316.27M | 0.35 | 4.32M | -22.57% | -$92.16M | 0.5 | |
| Allianz Asset Management Gmbh | $315.97M | 0.35 | 4.31M | +2.11% | +$6.53M | 0.54 | |
| UBS | $308.67M | 0.34 | 4.21M | +18.49% | +$48.17M | 0.09 | |
| First Trust | $306.42M | 0.34 | 4.18M | +1.59% | +$4.8M | 0.31 | |
| Standard Life | $288.77M | 0.32 | 3.94M | +4.73% | +$13.05M | 0.57 | |
| Swiss National Bank | $273.33M | 0.3 | 3.73M | -4.23% | -$12.07M | 0.18 | |
| Bank of Montreal | $305.51M | 0.29 | 3.59M | -23.07% | -$91.62M | 0.1 | |
| Robeco Institutional Asset Management B.V. | $262.46M | 0.29 | 3.58M | -0.45% | -$1.2M | 0.57 | |
| Voloridge Investment Management, LLC | $257.12M | 0.28 | 3.51M | New | +$257.12M | 0.95 | |
| Sumitomo Mitsui Trust Holdings | $255.25M | 0.28 | 3.48M | +0.29% | +$748,468.50 | 0.17 | |
| AQR Capital | $242.8M | 0.27 | 3.31M | -14.22% | -$40.25M | 0.38 | |
| Two Sigma | $234.16M | 0.26 | 3.2M | +16,724.6% | +$232.76M | 0.35 |